Omicron XBB.1.5 does not have mutations known to make people sicker, WHO says

Omicron XBB.1.5 does not have mutations known to make people sicker, WHO says


A man is getting a Covid-19 test at a Covid-19 mobile testing site as people lined up at the Times Square in New York City, on Dec 6, 2021.

Tayfun Coskun | Anadolu Agency | Getty Images

The omicron XBB.1.5 subvariant does not have any mutations known to make people sicker when they catch the virus, according to a World Health Organization risk assessment published on Wednesday.

But the WHO noted in the report that it doesn’t have any real-world data on how XBB.1.5 is affecting patients’ health, so it cannot draw any conclusions at this time about the severity of the subvariant.

The WHO said XBB.1.5 is one of the Covid subvariants that is most adept at dodging immunity from vaccination or infection. It is just as immune evasive as another subvariant in its family, XBB.1., which was the Covid variant that best dodged antibodies that block infections.

The global health organization said XBB.1.5 has a growth advantage in the U.S., particularly in the Northeast where it has rapidly become dominant. XBB.1.5 could cause cases to increase globally, but it’s difficult to know for sure because almost all of the data is coming from the U.S., according to the WHO. The organization said it needs more data on how fast XBB.1.5 is spreading in other countries.

Maria van Kerkhove, the WHO’s Covid-19 technical lead, said last week that XBB.1.5 is the most transmissible Covid subvariant to date. Scientists believe it has a growth advantage because it is highly immune evasive and binds more tightly to human cells, making it more infectious.

“It is the most transmissible subvariant that has been detected yet,” Van Kerkhove told reporters during a press conference in Geneva last Wednesday. “The reason for this are the mutations that are within this subvariant of omicron allowing this virus to adhere to the cell and replicate easily.”

In the U.S., XBB.1.5 is the only subvariant showing substantial growth right now. It rose from about 2% of cases in early to December nearly 28% in the first week of January, according to data from the Centers for Diesase Control and Prevention. It is causing more than 70% of new Covid cases in the Northeast.

Data on how well the vaccines hold up against XBB.1.5 is limited right now, though the subvariant is expected to cause more breakthrough infections. Lab studies have indicated other variants in the XBB family have proven adept at evading the antibodies generated by vaccination with the omicron boosters.

Although omicron subvariants have proven adept at causing breakthrough infections, Pfizer’s and Moderna’s vaccines are still generally preventing hospitalization and death. However, public health officials in the U.S. have emphasized that its particularly important for vulnerable groups, such as the elderly, to stay up to date on their shots to prevent severe illness.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More